ClinicalTrials.gg
AvailableNCT05959239Updated Dec 9, 2024

TB006 Expanded Access (EA) Compassionate Use

An expanded access record providing TB006 in Alzheimer Disease, sponsored by TrueBinding, Inc.. Available. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by TrueBinding, Inc. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Ages
55 Years and older
Sex
All
01

Study summary

This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.

Read the detailed description

A participant's physician who is interested in participating in this program will need to go to the company's website for further information and application forms.

02

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • Related Dementias
  • Expanded Access
  • TB006
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Lead sponsor

TrueBinding, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female participants > 55 years of age at the time of signing the .
  • The participant is diagnosed with symptomatic AD or related dementia, meeting the clinical criteria for AD with an estimated or actual (MMSE) score or 24 or less. All other medical conditions are stable and well managed. Clinical diagnosis of AD is consistent with the following:

    1. Probable AD, according to National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA).
    2. Meets the Fifth Edition (DSM 5) - Criteria for Major Neurocognitive Disorder (previously dementia).
  • There must be clear documentation of the participant's declining cognitive and functional status, any and all treatments attempted, and response (or lack of) to treatments.
  • The participant is not able to receive any of the current anti-AD medicines either due to intolerance or (s); or the participant's dementia has persistently declined despite receiving maximum allowable or tolerated doses of current anti-AD medicines, including aducanumab and lecanemab.
  • The participant is unable or ineligible to enroll in another clinical trial for their condition. This is defined as:

    1. No ongoing trial for which the participant may qualify.
    2. An ongoing trial, but the participant does not qualify.
    3. No ongoing trial site within 50 miles of the participant's home.
  • The investigator as well as the participant/caregiver must be informed of the potential risks and obligations of the program and decide whether the potential benefit outweighs the risk of receiving an therapy based on the participant's medical history and program eligibility criteria. The participant, and/or, in the case of reduced decision-making capacity, the legally acceptable representative(s) consistent with national law and ethics approval is/are able to read, understand, and provide written informed consent.
  • Has one (or more) identified adult program partner who either lives with the participant or has sufficient contact to provide assessment of changes in participant behavior and function over time and information on safety and tolerability; is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the clinic; agrees to accompany the participant to each program visit.
  • Able to comply with the program procedures, including the ability to travel to the named clinic for monthly visits.

Exclusion criteria

Exclusion criteria:

  • Any or uncontrolled medical condition, including but not limited to cardiovascular disease, respiratory disorder, , and hematology or clinical chemistry abnormality.
  • Has undergone major surgery or experienced trauma in the last 14 days.
  • Any condition or emergent intercurrent illness that, in the judgment of the investigator, could result in the risk of participation outweighing the potential benefit.
  • Unable to comply with this program protocol or has health concerns that may increase risk, in the opinion of the investigator.
  • Participated in a clinical trial with an investigation drug within the past 6 months.
  • Enrolled in a previous TB006 clinical trial and either did not complete the clinical trial or had a significant treatment-related Adverse event (AE) that could cause an undue risk.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • DrugTB006

    TB006 will be provided as single-use injectable glass vials.

06

Where to request access

No study locations are listed for this record.

07

References and documents

Related links

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05959239
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Jul 25, 2023
Last update
Dec 9, 2024

Study contacts

Truebinding, Inc.
Contact
info@truebinding.com
650-847-1117
Truebinding, Inc.
study director · TrueBinding, Inc.
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion